Targeting hypoxia in prostate cancer cells to increase treatment efficacy

Heather Nesbitt; niall byrne; Jenny Worthington; Stephanie McKeown; Declan McKenna

Targeting hypoxia in prostate cancer cells to increase treatment efficacy

Heather Nesbitt
, niall byrne
, Jenny Worthington
, Stephanie McKeown
, Declan McKenna

Prostate Cancer UK

Research output: Contribution to journal › Article › peer-review

Abstract

Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (

Original language	English
Pages (from-to)	209-210
Journal	Ulster Medical Journal
Volume	84
Issue number	3
Publication status	Published (in print/issue) - Oct 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

hypoxia
uHAP
OCT1002
bicalutamide
prostate cancer

Access to Document

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642251/

Cite this

@article{e759c8a8ea72438d9a293179573de572,

title = "Targeting hypoxia in prostate cancer cells to increase treatment efficacy",

abstract = "Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (",

keywords = "hypoxia, uHAP, OCT1002, bicalutamide, prostate cancer",

author = "Heather Nesbitt and niall byrne and Jenny Worthington and Stephanie McKeown and Declan McKenna",

year = "2015",

month = oct,

language = "English",

volume = "84",

pages = "209--210",

journal = "Ulster Medical Journal",

issn = "2046-4207",

publisher = "Ulster Medical Society",

number = "3",

}

TY - JOUR

T1 - Targeting hypoxia in prostate cancer cells to increase treatment efficacy

AU - Nesbitt, Heather

AU - byrne, niall

AU - Worthington, Jenny

AU - McKeown, Stephanie

AU - McKenna, Declan

PY - 2015/10

Y1 - 2015/10

N2 - Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (

AB - Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (

KW - hypoxia

KW - uHAP

KW - OCT1002

KW - bicalutamide

KW - prostate cancer

M3 - Article

SN - 2046-4207

VL - 84

SP - 209

EP - 210

JO - Ulster Medical Journal

JF - Ulster Medical Journal

IS - 3

ER -

Targeting hypoxia in prostate cancer cells to increase treatment efficacy

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this